Boryung Corporation

A003850

KR7003850005

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-07-16 pm EDT			5-day change	1st Jan Change
10,550 ^KRW	+0.57%		+0.67%	-11.27%

May. 29	LambdaVision, Incorporated announced that it expects to receive funding from Aurelia Foundry, Aurelia Foundry Management Company, LLC, Boryung Corporation, E2MC	CI
May. 16	Boryung Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Boryung Pharmaceutical Co., Ltd.'s Equity Buyback Plan Extended till January 3, 2020.

January 02, 2019

On January 3, 2019, the company announced that it has extended its plan duration till January 3, 2020.

Latest news about Boryung Corporation

LambdaVision, Incorporated announced that it expects to receive funding from Aurelia Foundry, Aurelia Foundry Management Company, LLC, Boryung Corporation, E2MC	May. 28	CI
Boryung Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 16	CI
Tranche Update on Boryung Corporation's Equity Buyback Plan announced on November 9, 2020.	Apr. 04	CI
Tranche Update on Boryung Corporation's Equity Buyback Plan announced on November 9, 2020.	Apr. 04	CI
Tranche Update on Boryung Corporation's Equity Buyback Plan announced on November 9, 2020.	Apr. 04	CI
Tranche Update on Boryung Corporation's Equity Buyback Plan announced on November 9, 2020.	Apr. 04	CI
Tranche Update on Boryung Corporation's Equity Buyback Plan announced on November 9, 2020.	Apr. 04	CI
Tranche Update on Boryung Corporation's Equity Buyback Plan announced on January 8, 2014.	Apr. 04	CI
Tranche Update on Boryung Corporation's Equity Buyback Plan announced on July 3, 2012.	Apr. 04	CI
Tranche Update on Boryung Corporation's Equity Buyback Plan announced on March 30, 2011.	Apr. 04	CI
Boryung Corporation's Equity Buyback announced on January 8, 2014, has expired with 132,205 shares, representing 0.24% for KRW 996.97 million.	Mar. 31	CI
Boryung Corporation's Equity Buyback Plan announced on March 30, 2011, has expired with 205,808 shares, representing 0.37% for KRW 1.19 million.	Mar. 31	CI
Boryung Corporation's Equity Buyback Plan announced on July 3, 2012, has expired with 332,770 shares, representing 0.61% for KRW 1,081.11 million.	Mar. 31	CI
Boryung Corporation's Equity Buyback Plan announced on February 3, 2006, has expired.	Mar. 31	CI
Boryung Corporation's Equity Buyback announced on November 9, 2020 has expired with 619,992 shares, representing 1% for KRW 10,013.49 million.	Mar. 31	CI
Boryung Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 11	CI
Boryung and Axiom Space Join Forces for Space Ventures	Jan. 12	MT
Intuitive Machines Partners With South Korea's Boryung; Announces COO Appointment, CFO Departure	Dec. 26	MT
Boryung Corporation(KOSE:A003850) dropped from KOSPI 200 Index	Dec. 14	CI
Boryung Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Axiom Space raises $350 mln in round led by Saudi, Korean investors	23-08-21	RE
Axiom Space, Inc. announced that it has received $350 million in funding from Boryung Corporation, AlJazira Capital Company	23-08-20	CI
Axiom Space, Inc. announced that it has received $350 million in funding from Boryung Corporation, AlJazira Capital Company	23-08-20	CI
Boryung Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
South Korea's FTC Imposes 40.9 Billion Won in Fines on Drug Firms for Bid-Rigging	23-07-21	MT

Boryung Corp, formerly Boryung Pharm Co Ltd, is a Korea-based company principally engaged in the manufacture and sale of pharmaceutical products. The Company mainly manufactures and distributes pharmaceutical products including antihypertensive drugs, gastrointestinal disorder drugs, antibiotics, gastric ulcer drugs, oral antibiotics, anticancer drugs and antihyperlipidemic drugs, among others. The Company distributes its products in domestic and overseas markets.

Sector

Pharmaceuticals

Calendar

2024-07-25 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Boryung Corporation

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

10,550 KRW

Average target price

15,333 KRW

Spread / Average Target

+45.34%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
BORYUNG CORPORATION	-11.27%	503M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+25.40%	45.35B
OTSUKA HOLDINGS CO., LTD.	+38.38%	24.34B
SANDOZ GROUP AG	+27.09%	16.51B
CIPLA LIMITED	+21.19%	14.6B
ZYDUS LIFESCIENCES LIMITED	+71.91%	14.27B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-11.63%	6.57B
ASPEN PHARMACARE HOLDINGS LIMITED	+13.07%	5.76B
STADA ARZNEIMITTEL	-8.87%	5.73B

Generic Pharmaceuticals

Boryung Corporation

Equities

A003850

KR7003850005

Pharmaceuticals

Boryung Pharmaceutical Co., Ltd.'s Equity Buyback Plan Extended till January 3, 2020.

Latest news about Boryung Corporation

Chart Boryung Corporation

Company Profile

Income Statement Evolution

Ratings for Boryung Corporation

Analysts' Consensus

EPS Revisions

Quarterly revenue - Rate of surprise

Sector Generic Pharmaceuticals